• Please refer to the Rebif^® SmPC for further monitoring details

Month

0

1

2

3

4

5

6

7

8

9

10

11

12

Hepatic Function

Periodically thereafter

Complete and differential blood cell counts and platelet counts

Periodically thereafter

Thyroid function

Every 6 months if abnormal at baseline

• Blood tests are recommended at regular intervals (months 1, 3 and 6) and periodically thereafter these should be more frequent when initiating Rebif^® 44µg

Summary of safety profile

The highest incidence of adverse reactions associated with Rebif^® therapy is related to flu-like syndrome. Flu-like symptoms tend to be most prominent at the initiation of therapy and decrease in frequency with continued treatment. Approximately 70% of patients treated with Rebif^® can expect to experience the typical interferon flu-like syndrome within the first six months after starting the treatment. Approximately 30% of patients will also experience reactions at the injection site, predominantly mild inflammation or erythema. Asymptomatic increases in laboratory parameters of hepatic function and decreases in white blood cells are also common.¹²

The majority of adverse reactions observed with interferon beta-1a are usually mild and reversible, and respond well to dose reductions. In case of severe or persistent undesirable effects, the dose of Rebif^® may be temporarily lowered or interrupted, at the discretion of the physician.¹²

Consult the Rebif^® Summary or Product Characteristics for full details.¹²